1 / 10

Glecaprevir - Pibrentasvir in Non-Cirrhotic Genotype 4, 5, or 6 ENDURANCE-4

This presentation discusses the findings of the ENDURANCE-4 study on the effectiveness and safety of glecaprevir-pibrentasvir in treating treatment-naïve and treatment-experienced patients with non-cirrhotic genotype 4, 5, or 6. The study demonstrates high rates of sustained virologic response (SVR12) and provides important insights for clinicians.

wrobinson
Download Presentation

Glecaprevir - Pibrentasvir in Non-Cirrhotic Genotype 4, 5, or 6 ENDURANCE-4

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 3 Treatment-Naïve and Treatment-Experienced Glecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 4, 5, or 6ENDURANCE-4 Source: Asselah T, et al. ClinGastroenterolHepatol. 2018;16:417-26.

  2. Glecaprevir-Pibrentasvirin Non-Cirrhotic Genotype 4, 5, or 6*ENDURANCE-4: Study Features *Note: ENDURANCE-4 was published in conjunction with ENDURANCE-2 and SURVEYOR-II (Part 4) Source: Asselah T, et al. ClinGastroenterolHepatol. 2018;16:417-26.

  3. Glecaprevir-Pibrentasvirin Non-Cirrhotic Genotype 4, 5, or 6ENDURANCE-4: Study Design 0 12 24 Week Glecaprevir-Pibrentasvir(n = 121) GT 4, 5, 6 No cirrhosis SVR12 Drug DosingGlecaprevir-pibrentasvir (100/40 mg) fixed dose combination; three pills once daily Source: Asselah T, et al. ClinGastroenterolHepatol. 2018;16:417-26.

  4. Glecaprevir-Pibrentasvirin Non-Cirrhotic Genotype 4, 5, or 6ENDURANCE-4: Baseline Characteristics Source: Asselah T, et al. ClinGastroenterolHepatol. 2018;16:417-26.

  5. Glecaprevir-Pibrentasvirin Non-Cirrhotic Genotype 4, 5, or 6ENDURANCE-4: Baseline Characteristics Source: Asselah T, et al. ClinGastroenterolHepatol. 2018;16:417-26.

  6. Glecaprevir-Pibrentasvirin Non-Cirrhotic Genotype 4, 5, or 6ENDURANCE-4: Results SVR12 (ITT analysis), Overall and by Genotype 50/51 51/51 50/51 50/51 120/121 75/76 26/26 19/19 Source: Asselah T, et al. ClinGastroenterolHepatol. 2018;16:417-26.

  7. Glecaprevir-Pibrentasvirin Non-Cirrhotic Genotype 4, 5, or 6ENDURANCE-4: Results SVR12 (ITT analysis), Overall and by Genotype 120/121 75/76* 26/26 19/19 *1 patient stopped drug on day 12 Source: Asselah T, et al. ClinGastroenterolHepatol. 2018;16:417-26.

  8. Glecaprevir-Pibrentasvirin Non-Cirrhotic Genotype 4, 5, or 6ENDURANCE-4: Adverse Events Source: Asselah T, et al. ClinGastroenterolHepatol. 2018;16:417-26.

  9. Glecaprevir-Pibrentasvir in Non-Cirrhotic Genotype 4, 5, or 6*ENDURANCE-4: Conclusions *Note: ENDURANCE-4 was published in conjunction with ENDURANCE-2 and SURVEYOR-II (Part 4) Source: Asselah T, et al. ClinGastroenterolHepatol. 2018;16:417-26.

  10. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.

More Related